EUCTR2009-013402-14-IT进行中（未招募）不适用
INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin - INTERCEPTOR-TRIA
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST0 个研究点开始时间: 2009年7月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed written informed consents prior to beginning protocol. 2. ? 18 years of age. 3. Histologically or cytologically confirmed diagnosis of HNSCC of oral cavity, oropharynx, hypopharynx or larynx. 4. Tumor tissue available for immunohistochemical staining of HPV and EGFR expression. (clinical protocol: 11. APPENDIX 3). 5. Stage III/IVa/IVb (UICC 2002 6th edition). Patients with tumor of hypopharynx and base of tongue stage II are eligible. 6. Not suitable for surgery disease at ENT evaluation. 7. Technically resectable disease needing demolitive surgery and with definitive cure rate improbable or medical contraindication for surgery. 8. Patient?s surgery refusal. 9. ECOG Performance Status 0-2 at study entry. 10. Neutrophils ? 1,5 x 109/L , platelet count ? 120 x 109/L and hemoglobin ? 10 g/dl Normal liver function, as follows: Total bilirubin ≤ 1,5 x ULN, Creatinine clearance ? 60 ml/min (Cockroft-Gault method). 11. Odontologic intervention completed from two weeks. 12. Nutritional evaluation. 13. Phisycal examination (clinical protocol: VALUTAZIONE BASALE 5.2.) 14. Effective contraception if risk of conception exists. 15. Psychological, familiar, social and geographic conditions that can guarantee the adhesion to the protocol and the follow-up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Distant metastasis. 2. Nasopharyngeal carcinoma WHO type II or III. 3. Prior surgery, excluding prior diagnostic biopsy. 4. Prior systemic chemotherapy and/or radiotherapy; Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy not indicated in the study protocol. 5. Medical or psychological condition that would not permit the patient to complete the trial or sign informed consent. Other concomitant anticancer therapy. 6. Known chronic heart failure. Clinically relevant coronary artery disease or history of a myocardial infarction within the last 12 months before study entry. 7. Active uncontrolled infection. 8. Known peripheral neuropathy ? grade 2 NCI-CTC version 3.0. 9. Previous or current malignancy except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix. 10. Pregnancy (absence confirmed by b-HCG test) or lactation period.
研究者
相似试验
Unknown
3 期
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus CisplatinSquamous Cell Carcinoma of the Head and NeckNCT00999700Gruppo Oncologico del Nord-Ovest282
进行中（未招募）
不适用
Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma - IILFLE09EUCTR2009-012337-29-ITFONDAZIONE ITALIANA LINFOMI ONLUS
尚未招募
不适用
Induction chemotherapy followed by chemoradiation in loco-regionally advanced nasopharyngeal carcinomaCTRI/2022/08/044617Jawaharlal Institute of Postgraduate Medical Education and Research
进行中（未招募）
不适用
Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck - RECETEUCTR2007-004280-22-DEniversitätsklinikum Schleswig-Holstein, Campus Lübeck: Klinik für Strahlentherapie
进行中（未招募）
不适用
Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.Inoperable squamous cell carcinoma of the head and neck.EUCTR2006-003381-33-SIInstitute of Oncology Ljubljana